TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00692978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate_1.5
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate_1.5
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate_3
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate_3
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate_6
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate_6
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP From Active 250 ug MDI Inhaler
Description: Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP From Active 250 ug MDI Inhaler
Description: Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
Study: NCT01919710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: for treatment of neutropenia
Study: NCT01165645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Given orally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04362410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab single dose subcutaneously injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab single dose subcutaneously injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab single dose subcutaneously injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose subcutaneously injection.
Study: NCT00634010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: 5 mg orally every 12 hours; additional capsules every 2 hours as needed.
Study: NCT02318823

Intervention type: OTHER
Group type: OTHER
Intervention: Beer (alcoholic)
Description: Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)

Intervention type: OTHER
Group type: OTHER
Intervention: Beer (alcoholic)
Description: Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (non-alcoholic beer)
Description: Non-alcoholic beer serves as Placebo.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (non-alcoholic beer)
Description: Non-alcoholic beer serves as Placebo.
Study: NCT01658098

Intervention type: BEHAVIORAL
Intervention: edinburgh postpartum depression scale questionary
Description: the investigators will apply the qusetionary one time only in the period of time described previously
Study: NCT01638117

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PAC14028-Vehicle
Description: PAC-14028 Cream Vehicle, Daily for up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC14028-0.1
Description: PAC-14028 Cream, 0.1%, Daily for up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC14028-0.3
Description: PAC-14028 Cream, 0.3%, Daily for up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC14028-1.0
Description: PAC-14028 Cream, 1%, Daily for up to 21 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, Daily for up to 21 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive
Description: Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Study: NCT02618954

Intervention type: OTHER
Group type: OTHER
Intervention: Articular ultrasound
Description: (Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
Study: NCT01365143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Radical Prostatectomy
Description: Robotic assisted radical prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Radical Prostatectomy
Description: Open radical prostatectomy
Study: NCT03061630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: D1.8.15 : GEMCITABINE 1000MG/M2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: D1: CISPLATIN 60G/M2
Study: NCT03124095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise Group
Description: The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
Study: NCT02308826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Turtle Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cool Little Kids
Study: NCT03178929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Adenosyl Methionine
Description: 2000mg, po
Study: NCT03916848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Micro-Macro SEEG Electrodes
Description: The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study.
Study: NCT00447759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200-400mg daily in divided doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: prescribed medication taken orally
Study: NCT04607525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines \[5\] \[6\] \[7\].

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D.
Study: NCT02582723

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein/high fat hard cheese
Description: Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein/low fat hard cheese
Description: Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein/high fat creme cheese
Description: Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
Study: NCT00568945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capadenoson (BAY68-4986)
Description: 4 mg BAY68-4986 for five days
Study: NCT00326469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: 120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
Study: NCT02727166

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrine
Description: Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
Study: NCT02624323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided central vein catheterization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided central vein catheterization.
Study: NCT03373487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The cognitive rehabilitation program ReMind
Description: Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The cognitive rehabilitation program ReMind
Description: Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining
Study: NCT00577161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine and rituximab
Description: days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine, rituximab, pixantrone
Description: days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
Study: NCT04922489

Intervention type: PROCEDURE
Intervention: Dental implant placement
Description: Dental implant placemente on edentulous jaw.
Study: NCT01020448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin (Decapeptyl®)
Description: One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
Study: NCT01938469

Intervention type: OTHER
Group type: OTHER
Intervention: Liquid Meal

Intervention type: OTHER
Group type: OTHER
Intervention: Solid Meal
Study: NCT04127149

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: The group uses an ultrasound device for the consultation.
Study: NCT01207661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Injection
Description: Intra Articular Injection of Mesenchymal cells to the knee joint
Study: NCT00514657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)
Study: NCT01566656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total lymphoid irradiation and anti-thymocyte globulin
Description: * TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~* ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~* Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~* GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0
Study: NCT02866110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Echo-planar Imaging of brain BOLD signal
Study: NCT02367365

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT00508248

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3 fatty acids
Description: 1g daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: olive oil capsule
Study: NCT00984763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel® + CPG 7909
Description: A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
Study: NCT03708822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Cisplatin and Nimotuzumab
Description: Intravenous nimotuzumab (200 mg on days 1, 8, and 15) ; Intravenous docetaxel (75 mg/m2 on day 1) ; Intravenous cisplatin (75 mg/m2 on day 1) ;
Study: NCT03379922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress balls
Description: Squeezing stress balls while receiving ESWL treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headphones
Description: Listening to music while receiving ESWL treatment
Study: NCT02975024

Intervention type: DEVICE
Intervention: laser speckle contrast imaging of the oral mucosa
Description: Non-invasive method to measure tissue blood perfusion applied for oral mucosa

Intervention type: DEVICE
Intervention: laser speckle contrast imaging of the oral mucosa
Description: Non-invasive method to measure tissue blood perfusion applied for oral mucosa

Intervention type: DEVICE
Intervention: wound fluid measurement
Description: Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.

Intervention type: DEVICE
Intervention: wound fluid measurement
Description: Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.

Intervention type: DEVICE
Intervention: quantitative determination of VEGF
Description: For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.

Intervention type: DEVICE
Intervention: quantitative determination of VEGF
Description: For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
Study: NCT05094466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive peer support sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive peer support sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive health coaching sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive health coaching sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Attend focus groups

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Attend focus groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Attend focus groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive handbook

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive handbook

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive handbook

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive navigation sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive navigation sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interview
Study: NCT01764113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary counselling
Study: NCT02645695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: routine pulmonary rehabilitation
Description: received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: routine pulmonary rehabilitation
Description: received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chest wall vibration technique
Description: administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chest wall vibration technique
Description: administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
Study: NCT01349725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-502
Description: Oral; multiple dose, escalating

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral; matching placebo
Study: NCT03739541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Benznidazole
Description: A single dose level of 100 mg; 200 μCi (7.4 MBq)
Study: NCT00947713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose human chorionic gonadotropin
Description: patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphen citrate plus HMG
Description: patients will receive Clomiphen Citrate plus HMG
Study: NCT01474499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate sodium and sorbitol rectal solution
Study: NCT02857998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: Oral administration, once daily
Study: NCT01941134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol-levonorgestrel
Description: Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
Study: NCT03045042

Intervention type: DRUG
Intervention: Enzyme Replacement Agent
Description: Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
Study: NCT02521467

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelets Rich Fibrin in healing of palatal donor tissue
Description: Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the other group is a control group, had no biologic in the palatal wound, only palatal stent
Study: NCT06168188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta® (pegfilgrastim)
Description: Intravitreal injection of Neulasta® (pegfilgrastim) after TON